Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
- Revenue in JPY (TTM)4.58tn
- Net income in JPY107.93bn
- Incorporated1925
- Employees47.46k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer AG | 7.93tn | -553.91bn | 4.38tn | 90.89k | -- | 0.7931 | 4.60 | 0.5525 | -3.31 | -3.31 | 47.41 | 33.03 | 0.4067 | 1.64 | 3.39 | 501,847.80 | -2.83 | -2.66 | -3.81 | -3.61 | 53.99 | 57.98 | -6.96 | -6.88 | 0.792 | 2.54 | 0.5473 | -- | -2.16 | 1.37 | 13.23 | -- | 0.9479 | -47.66 |
| UCB SA | 1.05tn | 181.34bn | 5.59tn | 9.38k | 30.81 | 3.20 | 19.91 | 5.34 | 5.48 | 5.48 | 31.62 | 52.77 | 0.3741 | 1.50 | 4.48 | 656,003.40 | 6.48 | 4.98 | 7.97 | 6.20 | 71.52 | 71.71 | 17.31 | 13.00 | 0.9858 | 8.91 | 0.2319 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| Daiichi Sankyo Co Ltd | 1.89tn | 295.76bn | 6.11tn | 19.77k | 20.68 | 3.71 | 16.76 | 3.24 | 155.87 | 155.87 | 994.10 | 869.69 | 0.5454 | 0.8726 | 4.24 | 95,434,150.00 | 8.55 | 5.72 | 10.87 | 7.11 | 77.96 | 72.15 | 15.68 | 11.03 | 1.85 | -- | 0.0876 | 49.57 | 17.77 | 13.95 | 44.47 | 17.77 | 29.01 | 20.79 |
| Alnylam Pharmaceuticals, Inc. | 339.44bn | -38.99bn | 6.26tn | 2.23k | -- | 374.68 | -- | 18.43 | -2.09 | -2.09 | 18.27 | 0.8858 | 0.5842 | 4.12 | 9.70 | 1,052,959.00 | -6.71 | -20.07 | -8.96 | -25.51 | 86.01 | 84.18 | -11.49 | -55.19 | 2.98 | -0.4627 | 0.8988 | -- | 22.97 | 59.21 | 36.82 | -- | -24.55 | -- |
| Haleon PLC | 2.22tn | 284.62bn | 6.70tn | 24.00k | 24.06 | 2.12 | -- | 3.02 | 0.1571 | 0.1571 | 1.22 | 1.79 | 0.3286 | 3.39 | 5.49 | 468,041.70 | 4.31 | 3.67 | 5.11 | 4.23 | 60.75 | 62.28 | 13.13 | 11.97 | 0.7791 | 8.48 | 0.3843 | 218.65 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| Sun Pharmaceutical Industries Ltd | 889.01bn | 191.17bn | 6.80tn | 43.00k | 35.53 | 5.57 | 28.87 | 7.65 | 47.18 | 45.60 | 219.42 | 300.99 | 0.5922 | 1.07 | 4.33 | -- | 12.79 | 9.19 | 16.38 | 12.51 | 79.56 | 74.04 | 21.60 | 16.24 | 2.33 | 272.98 | 0.0316 | 39.50 | 8.42 | 9.87 | 18.07 | 24.60 | 6.66 | 31.95 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 588.97bn | 138.03bn | 6.85tn | 20.24k | 49.32 | 7.23 | -- | 11.64 | 1.08 | 1.08 | 4.61 | 7.37 | 0.598 | 1.81 | 6.05 | 1,442,469.00 | 14.02 | 12.67 | 15.31 | 14.00 | 85.50 | 85.64 | 23.45 | 20.06 | 9.98 | -- | 0.0023 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| Takeda Pharmaceutical Co Ltd | 4.58tn | 107.93bn | 7.06tn | 47.46k | 66.43 | 1.01 | 8.12 | 1.54 | 66.83 | 66.83 | 2,880.43 | 4,407.01 | 0.3121 | 1.30 | 7.25 | 96,545,170.00 | 0.7367 | 1.71 | 0.8815 | 2.04 | 65.51 | 67.66 | 2.36 | 5.99 | 0.5202 | 2.52 | 0.3943 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| Merck KGaA | 3.63tn | 479.67bn | 8.24tn | 62.60k | 17.16 | 1.62 | 10.17 | 2.27 | 6.48 | 6.48 | 49.08 | 68.59 | 0.4312 | 1.88 | 4.89 | 340,745.30 | 5.71 | 6.04 | 7.12 | 7.70 | 59.21 | 61.15 | 13.24 | 13.80 | 0.8313 | 32.43 | 0.2252 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
Data as of Jul 07 2025. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
25.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 05 Jun 2025 | 74.98m | 4.71% |
| BlackRock Fund Advisorsas of 15 Apr 2025 | 59.40m | 3.73% |
| The Vanguard Group, Inc.as of 04 Jun 2025 | 55.32m | 3.48% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 13 Oct 2023 | 50.89m | 3.20% |
| BlackRock Japan Co. Ltd.as of 15 Apr 2025 | 36.01m | 2.26% |
| Nikko Asset Management Co., Ltd.as of 13 Oct 2023 | 34.71m | 2.18% |
| Daiwa Asset Management Co. Ltd.as of 30 May 2025 | 31.90m | 2.01% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 29.17m | 1.83% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jun 2025 | 19.94m | 1.25% |
| Geode Capital Management LLCas of 03 Jul 2025 | 17.46m | 1.10% |
More ▼
Data from 31 Dec 2024 - 03 Jul 2025Source: FactSet Research Systems Inc.
